In
this study, an intelligent drug delivery system (DDS) based
on implanted triboelectric nanogenerator (iTENG) and red blood cell
(RBC) is established for in situ hepatocellular carcinoma
(HCC) therapy. Apatinib (APA), as an oral antitumor drug, which can
inhibit the expression of vascular endothelial growth factor receptor-2
(VEGFR2) is loaded inside RBC, realizing the transform from oral formulation
to injection preparation. Multishape designed iTENG adapted for different
implant sites and environments can harvest biomechanical energy efficiently.
The electric field (EF) generated by the iTENG can increase the release
of APA, and the release will decrease quickly when the EF disappears,
which shows that the DDS is highly controllable. The controllable
DDS demonstrates an exciting killing ability of HCC cells both in vitro and in vivo with strikingly reduced
APA dosage. After implantation, the self-powered DDS has a prominent
therapeutic effect of HCC-bearing rabbits, which is expected to be
applied in clinical medicine.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.